1. Tackling Atopic Dermatitis

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the Unite States.

3. What Is AD?

4. Outside-In Hypothesis External Factors Contribute to Barrier Dysfunction

5. Skin Barrier Dysfunction Predictive of AD

6. Other Factors in Barrier Dysfunction

7. Inside-Out Hypothesis Immune Dysregulation + Inflammation = AD

8. Inside-Out Hypothesis Role of Increased PDE4

9. Key Takeaway No. 1

10. Prevalence of AD in Specific Populations

11. Clinical Manifestations of AD

12. Clinical Manifestations of AD (cont) Older Children and Adults

13. Importance of Differential Diagnosis

14. Burden of AD on Children and Caregivers

15. Pediatric Comorbidities

16. Key Takeaway No. 2

17. Determining Severity of AD

18. Mild to Moderate to Severe AD

19. Concerns for Skin Infections

20. Key Takeaway No. 3

21. Therapeutic Goals and Care Management

22. Care Management: Topical Corticosteroids

23. Care Management: Other Pharmacotherapy

24. Systemic Agents to Treat Severe AD

25. Key Takeaway No. 4

26. Creating the Action Plan

27. Written Action Plan

28. Barriers to Adherence

29. Key Takeaway No. 5

30. Concluding Remarks

31. Abbreviations